Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
Healthcare
$27.96 +0.47%
+$0.16 today
- Market cap
- $2.20B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
52W Low $19.52High $35.79
Volume 0.75M
Average 0.94M
Balance Sheet
Inspect the capital base behind the business.
Assets
$582.98M
FY 2025 · Annual
-26.4% YoYLiabilities
$55.82M
FY 2025 · Annual
+23.1% YoYEquity
$527.16M
FY 2025 · Annual
-29.4% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 39.14M | 29.43M | 34.81M | 28.36M | 28.87M |
| Short-term Investments | 369.11M | 275.52M | 386.88M | 696.93M | 489.7M |
| Net Receivables | 172K | 347K | 4.53M | 700K | 2.02M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 5.47M | 21.18M | 14.08M |
| Total Current Assets | 410.84M | 317.69M | 431.69M | 747.16M | 534.66M |
| Property, Plant & Equipment (Net) | 6.52M | 7.75M | 6.64M | 8.24M | 7.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 104K | 104K | 107K | 9.75M | 13.36M |
| Total Non-current Assets | 33.82M | 35.04M | 33.93M | 45.18M | 48.32M |
| Total Assets | 444.65M | 352.74M | 465.63M | 792.34M | 582.98M |
| Account Payables | 1.23M | 3.34M | 3.49M | 3.27M | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.55M | 990K | 3.99M | 942K | 1.23M |
| Total Current Liabilities | 16.53M | 18.61M | 31.13M | 39.5M | 50.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.35M | 5.33M | 4.4M | 3.47M | 4.04M |
| Total Non-current Liabilities | 8.65M | 7.92M | 5.33M | 5.83M | 4.83M |
| Total Liabilities | 25.18M | 26.53M | 36.46M | 45.34M | 55.82M |
| Common Stock | 47K | 47K | 56K | 66K | 67K |
| Retained Earnings | (1.14B) | (1.26B) | (1.4B) | (1.56B) | (1.81B) |
| Accumulated OCI | 1.89M | 1.26M | 3.31M | 3.31M | 3.63M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 419.48M | 326.2M | 429.17M | 747.01M | 527.17M |
| Total Debt | 3.04M | 4.03M | 2.54M | 3.81M | 2.34M |
| Net Debt | (36.1M) | (25.4M) | (32.27M) | (24.54M) | (26.54M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $27.0M |
| Short-term Investments | $623.4M |
| Receivables | $355.0K |
| Other Current | $13.1M |
| Total Current Assets | $663.7M |
| PP&E (Net) | $20.9M |
| Intangible Assets | $27.2M |
| Other Non-current | $9.7M |
| Total Non-current Assets | $57.8M |
| Total Assets | $721.5M |
Analysis
Selected assets total $721.5M for Latest. The largest visible component is Short-term Investments at $623.4M, about 86.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 8-K | Current report | Sep 22, 2026 |
How much cash does CLDX have?
Celldex Therapeutics, Inc. (CLDX) reported $28.87M in cash and equivalents in fiscal 2025.
How much debt does CLDX carry?
Celldex Therapeutics, Inc. (CLDX) reported $2.34M of total debt, with net debt of -$26.54M.
Continue the stock analysis
Jump to another research area for this company.